Intellia Therapeutics (NTLA) Announces CFO Transition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St on track for subdued September start as high yields, oil prices dent sentiment
- Oil up more than 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Intellia Therapeutics Announces CFO Transition
June 26, 2024 7:30 AM EDTCAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Edward Dulac as Executive Vice President, Chief Financial Officer (CFO), and Treasurer, effective July 22, 2024. Mr. Dulac will succeed Glenn Goddard who will step down from his role effective June 30, 2024.
Mr. Dulac is a highly accomplished biotechnology business leader and joins Intellia with more than 20 years of combined finance, business development and corporate strategy experience. Most recently, Mr. Dulac... More
